We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Bone Mineral Density (BMD) in HIV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00146094
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : August 30, 2011
Information provided by:

September 2, 2005
September 5, 2005
August 30, 2011
March 2003
Not Provided
BMD evolution and modification during 2 years of follow-up, compared between treated and untreated subjects
Not Provided
Complete list of historical versions of study NCT00146094 on ClinicalTrials.gov Archive Site
  • BMD (baseline, and at 2 years) according to:
  • - calcium intake, physical activity,
  • - CD4 lymphocyte count, HIV viral load,
  • - bone metabolism biological markers (osteocalcine, C telopeptide collagen type I in urine),
  • - leptine, parathormone, 25 OH D3
Not Provided
Not Provided
Not Provided
Bone Mineral Density (BMD) in HIV Infection
Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients

Osteopenia and osteoporosis are increasingly reported in HIV-infected patients, and appear to be more frequent than in general population. However, pathogenesis remains unclear, and published studies still give non concordant results.

We therefore started a prospective study, to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis. BMD evolution over a 2-years period of follow-up, will be compared between patients starting ARV therapy, and subjects without HAART (no indication of treatment). A correlation between BMD and several factors will be looked at (see below).

This study with individual direct benefice, is conducted in 3 outpatients clinics (Strasbourg, Colmar, Mulhouse) in collaboration with the rheumatologic teams. 60 patients are planned to be included over a 3-years inclusion period

Not Provided
Not Provided
Primary Purpose: Basic Science
  • Osteopenia
  • Osteoporosis
Procedure: BMD Measurement
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • HIV-1 infected men, Caucasian, age > 18 years, ARV-naïve

Exclusion Criteria:

  • HIV-infected women, subjects < 18 years, non-Caucasian men, ARV-experienced patients, subjects not able or willing to give informed consent, endocrine disease or treatment which could affect bone metabolism
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Emmanuel LAVOUE, Directeur Adjoint, University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: David REY, MD Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP